Crystal structure-based comparison of two NAMPT inhibitors.

about

Crystal structure-based comparison of two NAMPT inhibitors.

Item

http://www.wikidata.org/entity/Q38635017

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Crystal structure-based comparison of two NAMPT inhibitors.

@en

type

Item

label

Crystal structure-based comparison of two NAMPT inhibitors.

@en

prefLabel

Crystal structure-based comparison of two NAMPT inhibitors.

@en

P1476

Crystal structure-based comparison of two NAMPT inhibitors.

@en

P2093

Qiang Zhao

http://www.w3.org/2001/XMLSchema#string

Sai-Long Zhang

http://www.w3.org/2001/XMLSchema#string

Shuo Han

http://www.w3.org/2001/XMLSchema#string

Tian-Ying Xu

http://www.w3.org/2001/XMLSchema#string

Zhen-Lin Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor

Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence

Metrnl: a secreted protein with new emerging functions

Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase

Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis.

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.

P2888

aps.2017.80

P304

294-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/APS.2017.80

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chao-Yu Miao

P577

2017-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091390806

http://www.w3.org/2001/XMLSchema#string

P698

28858298

http://www.w3.org/2001/XMLSchema#string

P932

5800471

http://www.w3.org/2001/XMLSchema#string